GreenLight licenses mRNA shingles vaccine to Serum Institute following a $10M investment
GreenLight Biosciences has come a long way from trying to shake up the pesticides market.
The Medford, MA biotech signed a deal Monday with the Serum Institute of India to design three mRNA products, including a shingles vaccine, for development, manufacturing and commercialization in a number of markets around the world.
GreenLight will retain the rights to North America, Europe, Australia, New Zealand, China, Japan and South Korea, while SII will get a tech transfer to work in Africa, Latin America, the Middle East and much of Asia. The deal piggybacks off of a $10 million investment made by Serum Life Sciences in November 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
